Tie-2 Activator Reduces Intraocular Pressure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for elevated intraocular pressure and ocular hypertension associated with glaucoma are inadequate in effectively reducing pressure within the eye, leading to potential permanent vision loss if not diagnosed or treated promptly.
Innovation Solution
Administration of a therapeutically-effective amount of a Tie-2 activator, which activates Tie-2 signaling by inhibiting human protein tyrosine phosphatase beta (HPTPβ), thereby reducing intraocular pressure by promoting protein phosphorylation and stabilizing the vasculature associated with the trabecular meshwork.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for elevated intraocular pressure are used, then the treatment can be administered, but the pressure reduction is inadequate and vision loss risk remains high
Solution Approach 1:
The patent changes the molecular target parameter from conventional IOP-lowering agents to Tie-2 activators that modulate angiopoietin signaling. This parameter change enables superior pressure reduction (0.1-9 mmHg) by activating Tie-2 receptor signaling, which stabilizes the trabecular meshwork vasculature and improves aqueous humor outflow, thereby reliably reducing intraocular pressure and mitigating vision loss risk.
2Reliability
If Tie-2 activator is administered, then intraocular pressure is effectively reduced, but the mechanism of action involves complex protein phosphorylation and vascular stabilization
Solution Approach 1:
The patent uses Tie-2 activators as intermediary substances that bind to and activate the Tie-2 receptor. This intermediary mechanism simplifies the overall therapeutic approach by focusing on a single activated pathway (angiopoietin-Tie-2 signaling) that cascades into multiple beneficial effects including protein phosphorylation, vascular stabilization, and improved aqueous humor outflow, thereby achieving reliable pressure reduction through a coordinated biological response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Tie-2 activator effectively reduces intraocular pressure by 0.1 mmHg to 9 mmHg, providing a therapeutic benefit in treating glaucoma and ocular hypertension, thereby mitigating the risk of vision loss.
Implementation Method 1
activates Tie-2 signaling by inhibiting human protein tyrosine phosphatase beta (HPTPβ), thereby reducing intraocular pressure by promoting protein phosphorylation
Data Source
AI summary
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.